Elicio Secures Undisclosed Funding After Phase II Trial Miss
ELTX•After its Phase II trial failed to meet primary endpoints, Elicio secured an undisclosed capital infusion in early July to extend its cash runway. The funding will support continued development of its lead immunotherapy candidate.
1. Fresh Capital Infusion
Elicio announced a fresh capital raise in early July, though the exact amount was not disclosed. The financing was completed weeks after the company’s Phase II trial failed to meet its primary endpoints.
2. Implications for Development Runway
The newly secured funds are earmarked to extend Elicio’s cash runway and support ongoing development of its lead immunotherapy candidate. Management expects the runway extension to finance key preclinical and early clinical activities moving forward.
